The CancerConnect Triple-Negative Breast Cancer Newsletter

TraceyS

Stay Current With Triple-Negative Breast Cancer Treatment Advances & Connect with Others

CancerConnect publishes daily cancer news, original articles and "tips" on the management of Triple-Negative Breast Cancer. These are available in our monthly Triple-Negative Breast Cancer newsletter.

Stay Current - Connect With Other Triple-Negative Breast Cancer Patients

Join The CancerConnect Community: Connect with others and receive regular updates

Sign up for the Triple-Negative Breast Cancer Newsletter Here

Comments

Triple Negative Breast Cancer

FEATURED

COMMUNITY

Trodelvy (sacituzumab govetecan) Treatment for Triple Negative Breast Cancer

Trodelvy™ FDA approved for treatment of triple negative breast cancer - ESMO update confirms effectiveness and safety.

Cancer Connect

Zejula - Keytruda Combination Therapy in TNBC

Precision Cancer Medicine Combination of Zejula and Keytruda Promising in Triple Negative Breast Cancer

MedMaven

Tecentriq Immunotherapy Treatment of Breast Cancer

Tecentriq improves outcomes of advanced TNBC when combined with Nab-paclitaxel but not paclitaxel.

MedMaven

New Breakthrough May Advance Triple Negative Breast Cancer Treatment

Drs. From Scripps believe that Targaprimir-96 could be the next TNBC treatment?

Cancer Connect

Obesity Linked with Triple-Negative Breast Cancer

Cancer Connect

Iniparib Promising in Metastatic Triple-negative Breast Cancer

Cancer Connect

To Remain Strong and Carry On: A Triple Neg Breast Cancer Survivors Story

Dr. Bhuvaneswari Ramaswamy of the OSU Arthur G. James Cancer Hospital answers frequently asked questions about TNBC

Cancer Connect

Update on Strategies to Improve Treatment for Triple Negative Breast Cancer

Keytruda, Tecentriq, and Sacituzumab Govitecan (IMMU-132) are promising TNBC treatment advances.

Cancer Connect

Breast-Conserving Therapy May Outperform Mastectomy Alone for Women

The role of surgery in the management of TNBC.

Cancer Connect

Erbitux May Increase Response Rates in Metastatic Triple-Negative Breast Cancer

Erbitux May Increase Response Rates in Metastatic Triple-Negative Breast Cancer.

Cancer Connect